Why the study?
Does platelet glycoprotein IIb/IIIa receptor blockade reduce ischemic complications in patients with acute coronary syndromes or undergoing percutaneous coronary revascularization?
Does platelet glycoprotein IIb/IIIa receptor blockade reduce ischemic complications in patients with acute coronary syndromes or undergoing percutaneous coronary revascularization?
Platelet glycoprotein IIb/IIIa receptor blockade represents a promising pharmacological strategy for reducing ischemic complications in acute coronary syndromes and percutaneous coronary interventions.
Answers are grounded in this paper and cite their sources.
Supports adjunctive GP IIb/IIIa blockade in PCI; leaves open definitive ACS role pending randomized trials.
Several of the adverse events that occur in acute coronary syndromes and after percutaneous coronary revascularization procedures are believed to be mediated by platelets. Recently, using molecular biology techniques, the platelet glycoprotein IIb/IIIa receptor was identified as the final common pathway for platelet aggregation. Thus, blocking the action of this receptor would seem to be an attractive proposition for reducing ischemic complications. A monoclonal antibody was the first agent in this new pharmacological family to be designed, but several peptide and peptide-like substances have subsequently been developed. This paper reviews the development of this class of agents and the various preclinical and clinical trials that have been undertaken. Early studies evaluated such agents during percutaneous coronary revascularization procedures. Because of the overwhelming benefits observed in such patients, together with the current limitations of treatments for acute coronary syndromes, the scope of investigations has been extended. Preliminary reports have been encouraging.
No takes yet. Share an insight, caveat, or question.
Mak et al. (1998) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: